Personalised Medicine: Statistics for Companion Diagnostics
Date for Webinar: Thursday 4th May. 2-3.30pm UK time
Personalised medicines - which are designed to treat particular groups of patients - are becoming increasingly prominent. In order to identify patients suitable for treatment a companion diagnostic assay is often needed. The Personalized Medicines Coalition (PMC) recently published an article stating that 25% of NME approved by FDA in 2016 included a companion diagnostic.
This webinar will introduce and examine some of the considerations required for statisticians working in the field of companion diagnostics and will include information from an FDA (CDRH) speaker and perspectives/ case-studies from representatives from both a pharmaceutical company and a diagnostic company.
CLICK HERE TO VIEW THE FLYER
Meijuan Li, CDRH
Peter Cooper, Qiagen
Rachel Hodge, AstraZeneca
Meijuan Li (CDRH)
Applications of personalized medicine are becoming increasingly prominent. A companion diagnostic assay (CDx) is often desired for patient enrollment in device-drug pivotal clinical trial(s) so that FDA can ensure that appropriate clinical and analytical validation studies are planned and carried out for CDx. However, such a requirement may be difficult or impractical to accomplish. A clinical trial assay (CTA) instead of CDx may be used for patient enrollment in drug-device pivotal clinical trial(s). A supplemental agreement study of CDx and CTA will be required to bridge the clinical results from CTA to CDx. In this webinar, we will discuss statistical challenges in study design and data analysis for bridging study. Particularly, we aimed to provide statistical methods on how to estimate the drug efficacy in CDx intended use population using results from bridging study and CTA-drug pivotal clinical trial.
Peter Cooper (Qiagen)
Perspective from Diagnostic Company
Rachel Hodge (Astrazeneca)
Perspective/Case-study from Pharmaceutical Company
CLICK HERE TO REGISTER! (Attendance is free)
iCalendar PLACEHOLDER - PLEASE REGISTER WITH PSI to attend. You will be sent dial-in details for the webinar during the week of the webinar as long as you have registered with PSI first.
***Please note that this registration provides PSI with your details in order to register interest for the Webinar (please note there is a limited number of participants so please only register if you plan to attend).
In the week before the webinar you will be sent another email and you will need to REGISTER AGAIN with the WEBINAR (GoToWebinar) to get your personal dial-in details to attend the webinar.***